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Abstract
Background: Part of the pathophysiology in septic shock is a progressive activation of the endothelium and platelets
leading to widespread microvascular injury with capillary leakage, microthrombi and consumption coagulopathy.
Modulating the inflammatory response of endothelium and thrombocytes might attenuate this vicious cycle and
improve outcome.
Method: The CO-ILEPSS trial was a randomised, placebo-controlled, double-blind, pilot trial. Patients admitted to the
intensive care unit with septic shock were randomised and allocated in a 2:1 ratio to active treatment with dual
therapy of iloprost 1 ng/kg/min and eptifibatide 0.5 μg/kg/min for 48 h or placebo. The primary outcomes were
changes in biomarkers reflecting endothelial activation and disruption, platelet consumption and fibrinolysis. We
compared groups with mixed models, post hoc Wilcoxon signed-rank test and Mann-Whitney U test.
Results: We included 24 patients of which 18 (12 active, 6 placebo) completed the full 7-day trial period and
were included in the per-protocol analyses of the primary outcomes. Direct comparison between groups showed
no differences in the primary outcomes. Analyses of within-group delta values revealed that biomarkers of endothelial
activation and disruption changed differently between groups with increasing levels of thrombomodulin (p = 0.03) and
nucleosomes (p = 0.02) in the placebo group and decreasing levels of sE-Selectin (p = 0.007) and sVEGFR1 (p = 0.005) in
the active treatment group. Platelet count decreased the first 48 h in the placebo group (p = 0.049) and increased from
baseline to day 7 in the active treatment group (p = 0.023). Levels of fibrin monomers declined in the active treatment
group within the first 48 h (p = 0.048) and onwards (p = 0.03). Furthermore, there was a significant reduction in SOFA
score from 48 h (p = 0.024) and onwards in the active treatment group.
Intention-to-treat analyses of all included patients showed no differences in serious adverse events including bleeding,
use of blood products or mortality.
Conclusion: Our results could indicate benefit from the experimental treatment with reduced endothelial injury,
reduced platelet consumption and ensuing reduction in fibrinolytic biomarkers along with improved SOFA score.
The results of the CO-ILEPSS trial are exploratory and hypothesis generating and warrant further investigation in a
large-scale trial.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: rab@regionsjaelland.dk
†Rasmus Ehrenfried Berthelsen and Sisse Rye Ostrowski contributed equally
to this work.
1Department of Anesthesiology and Intensive Care, Zealand University
Hospital, Roskilde, University of Copenhagen, Copenhagen, Denmark
Full list of author information is available at the end of the article
Berthelsen et al. Critical Care          (2019) 23:301 
https://doi.org/10.1186/s13054-019-2573-8
(Continued from previous page)
Trial registration: Clinicaltrials.com, NCT02204852 (July 30, 2014); EudraCT no. 2014-002440-41
Keywords: Septic shock, Pathologic processes, Infection, Endothelium, Platelets, Iloprost, Eptifibatide, Platelet
aggregation inhibitors
Introduction
Septic shock is a leading cause of death in the intensive
care unit (ICU) with mortality rates above 40% [1, 2].
Treatment strategies consist of early recognition and diag-
nosis to facilitate timely initiation of antibiotic therapy
and supportive care [3]. A series of pathogenic events are
responsible for the transition from sepsis to septic shock.
The initial reaction to infection is a neurohumoral, gener-
alised pro- and anti-inflammatory response [4, 5] resulting
in mobilisation and/or “spill over” of plasma substances
and excessive cellular, coagulation and endothelial activa-
tion. The proinflammatory response induces widespread
endothelial and microvascular injury resulting in dissemi-
nated intravascular coagulation with microvascular
thrombosis, consumptive thrombocytopenia, coagulopa-
thy, bleeding and a loss of endothelial integrity ultimately
leading to capillary leakage, tissue oedema, tissue ischae-
mia and shock [5–7]. In the later stages of sepsis, im-
munodeficiency is a critical component of the pathology
that causes multiple organ failure and death [8].
There are three major pathogenic pathways associated
with the coagulopathy in sepsis: (1) tissue factor-mediated
thrombin generation, (2) dysfunctional anticoagulant
pathways and (3) blocked fibrinolysis [9]. Treatment strat-
egies aimed at reducing coagulation activation with anti-
thrombin [10], tissue factor pathway inhibitor [11] and
activated Protein C [12, 13] have all failed to show im-
proved survival in large clinical trials refuting this as a
pathophysiological explanation.
The platelets and endothelium are interdependent in the
vicious cycle of endothelial damage, microcirculatory
failure, consumptive thrombocytopenia, coagulopathy,
bleeding, immunodeficiency, tissue ischaemia, shock, organ
failure and death, in patients with severe sepsis/septic
shock. Selective targeting of either platelets or the endothe-
lium may be sufficient to prevent the progressively more
activated and damaged endothelium and activation of the
platelets [14].
Prostacyclin is an endogenously produced molecule
with anti-platelet, vasodilatory and cytoprotective prop-
erties released from the healthy endothelium as part of
the natural anticoagulation system [15]. Intravenous
prostacyclin in doses of 0.5–2.0 ng/kg/min has been re-
ported to be successful at achieving endothelial modulat-
ing/preserving effects in patients with traumatic brain
injury, without significant haemodynamic or platelet ag-
gregation complications [16, 17].
Eptifibatide is a platelet glycoprotein (GP) IIb/IIIa re-
ceptor inhibitor that prohibits clot development in a pre-
dictable and easy controllable way. Inhibition of the
GPIIb/IIIa receptor does not alter the paracrine function
of platelets, which is considered a crucial part of main-
taining vascular integrity and preventing haemorrhage in
conditions with inflammation [18, 19]. Animal studies
have reported that treatment with GPIIb/IIIa inhibitor
protects against endothelial dysfunction in experimental
endotoxemia [20, 21]. Furthermore, casuistic findings
have shown that GPIIb/IIIa inhibition leads to clinically
relevant thrombolysis in patients with mechanical pros-
thetic mitral valve thrombosis [22, 23].
The objective of the CO-ILEPSS trial was to investi-
gate safety and efficacy of a combined infusion of low-
dose prostacyclin (iloprost) and GPIIb/IIIa inhibitor
(eptifibatide) for 48 h in patients with septic shock. We
hypothesised that this dual treatment with iloprost and
eptifibatide would deactivate the endothelium and restore
vascular integrity, reduce formation of microvascular
thrombosis and dissolve existing thrombi in the microcir-
culation and maintain platelet counts leading to improved
platelet-mediated immune function and reduced risk of
bleeding. Compared to the standard treatment (placebo),
this was expected to translate into reduced organ failure
and improved outcome in patients with septic shock.
Methods
Design
The CO-ILEPSS trial was an investigator-initiated single-
centre randomised, placebo-controlled, double-blind
phase 2a trial in patients with septic shock.
The trial was conducted from October 2014 to May
2016, and there were no significant changes to the trial
protocol during the course of the trial. The trial is re-
ported in accordance with the CONSORT statement
[24], and a populated CONSORT checklist is available in
Additional file 1. The trial was approved by the regional
ethics committee, and all patients and/or their next of
kin gave informed consent to participate. The full trial
protocol is available in Additional file 2.
Participants
Patients were allocated in a 2:1 ratio with 15 intention-
to-treat (ITT) patients allocated to active treatment and
9 ITT patients allocated to control treatment (placebo).
Patients who dropped out or were withdrawn from the
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trial prior to day 7 were replaced to ensure adequate
data points, and 12 active treatment and 6 placebo pa-
tients, respectively, were treated as per protocol (PP). To
replace patients, who were withdrawn, unblinded trial
personal added envelopes containing the same allocation
as the ones who dropped out and we recruited and re-
randomised new patients.
We screened patients admitted to the intensive care
unit (ICU) at Nordsjaellands Hospital (NOH) during the
inclusion period. Patients were screened within 24 h of
admission according to the following inclusion criteria:
– Adult intensive care patients (age ≥ 18 years)
– Sepsis, defined as suspected or confirmed site of
infection or positive blood culture and ≥ 2 of 4
systemic inflammatory response syndrome (SIRS)
criteria fulfilled within the last 24 h:
a. Temperature ≤ 36 °C or ≥ 38 °C
b. Heart rate ≥ 90 beats per minute
c. Mechanical ventilation for acute respiratory
process or respiratory rate ≥ 20 breaths per
minute or PaCO2 < 4.2 kPa
d. WBC ≥ 12,000/mm; OR ≤ 4000/mm OR > 10%
bands
– Septic shock within the last 24 h, defined as:
a. Hypotension (MAP < 70 mmHg, lactate 4 mmol/
l) despite ongoing resuscitation with fluids
(crystalloids, colloids, blood products) within the
last 24 h or
b. ≥ 30 ml/kg ideal body weight (IBW) fluid
(crystalloids, colloids, blood products) given in
the last 24 h and
c. Need for vasopressor/inotropic agents
(noradrenaline, adrenaline or dopamine) within
the last 24 h
– Can be randomised into trial and dosed < 24 h after
septic shock diagnosis (the time point for the septic
shock diagnosis corresponds to the time point where
the vasopressor/inotropic therapy is initiated) and
– Consent is obtainable
A full description of the inclusion and exclusion cri-
teria is provided in Additional file 3.
Randomisation
The random allocation sequence was computer gener-
ated, and allocation pages were packed in sealed opaque
envelopes. The envelopes were prepared by the principal
investigator (SRO) at Rigshospitalet (RH) and delivered
at the trial site NOH. At NOH, the envelopes were
stored in a locked office at the post-anaesthesia care unit
(PACU) located in a separate building from the ICU.
The local investigators (REB and MHB) did not have ac-
cess to this office. When a patient fulfilled inclusion cri-
teria and consent had been obtained, randomisation was
done by placing a phone call from the ICU to a nurse at
the PACU. The nurse then opened the next envelope in
line and prepared the trial drug or placebo according to
the instructions. Syringes containing trial drug or pla-
cebo drug were then delivered to the investigator (REB)
at the ICU where trial treatment was initiated.
Intervention
Patients allocated to the active treatment arm received
dual infusions of prostacyclin (iloprost) 1.0 ng/kg/min
and GPIIb/IIIa inhibitor (eptifibatide) 0.5 μg/kg/min for
48 h. Iloprost and eptifibatide were both diluted in saline
to a concentration with which the targeted treatment
was achieved with an infusion of 4 ml/h. Treatment in
the placebo group consisted of dual infusions of normal
saline 4ml/h for 48 h. The infusions of both active and
placebo treatment were given either in two separate legs
of a central venous catheter or in two separate periph-
eral venous catheters.
Outcomes
The primary outcome of the CO-ILEPSS trial was di-
vided in three different measures. These were:
1) Change in biomarkers indicative of endothelial
activation and damage (sE-selectin, syndecan-1,
soluble thrombomodulin (sTM), sVE-cadherin,
nucleosomes, vascular endothelial growth factor
(VEGF) and soluble vascular endothelial growth
factor receptor 1 (sVEGFR1)) from baseline to 48 h
post-randomisation
2) Change in platelet count from baseline to 48 h
post-randomisation
3) Change in D-dimer and fibrin split products
indicative of fibrinolysis (fibrin monomer complex,
fibrin degradation products, D-dimer) from baseline
to 48 h post-randomisation.
The reason for having three primary sub-endpoints was
that they reflect different effects of active treatment on the
vascular system that we wished to evaluate, i.e. endothelial
activation, platelet consumption and fibrinolysis.
Secondary outcomes included severe bleeding (intracra-
nial or clinical bleeding with the use of 3 RBC units or
more/24 h); use of blood products in the ICU post-ran-
domisation; mortality at days 7, 30 and 90; changes in Se-
quential Organ Failure Assessment (SOFA) score from
baseline; and days of vasopressor, mechanical ventilation
and renal replacement therapy (RRT) post-randomisation.
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Sample size/power calculation
The sample size for the CO-ILEPSS trial was not based
upon a power calculation because there were no avail-
able data on the specific active dual drug therapy vs pla-
cebo in patients with septic shock.
However, in a previous study of safety and efficacy of
prostacyclin vs placebo in patients undergoing Whipple
surgery, post-operative levels of sVE-cadherin increased
1978 ± 461 pg/ml in the placebo group [25]. Based on
this, we would be able to detect a difference of 33% in
sVE-cadherin increase between groups with 12 patients
in the active treatment group vs 6 patients in the pla-
cebo group, with a power of 0.8 and an alfa of 0.05.
Blinding
The CO-ILEPSS trial was a double-blind, placebo-controlled
trial, and all participants, next of kin, caregivers, investiga-
tors and sponsors were blinded for the trial allocation.
Both trial medications were colourless when diluted in
saline, and it was impossible to distinguish the syringes
with trial medicine from those with saline. Since the num-
ber of patients in the different groups was unequal, it was
not possible to maintain blinding during the statistical
analyses, but these were conducted according to the statis-
tical analysis plan generated as part of the trial protocol.
Biomarker analyses
Blood samples for the analyses of biomarkers were drawn
pre-study drug/placebo administration, post 6 h, 24 h, 48
h, 72 h and 120 h. All samples were transferred to the local
Blood Bank at the trial site for further processing (centri-
fugation, plasma aliquoting and freezing) and stored at −
80 °C for later analyses at the Dept. of Clinical Immun-
ology, Blood Bank, Copenhagen University Hospital,
Rigshospitalet. In brief, biomarkers were analysed by com-
mercially available enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s recommenda-
tions: Syndecan-1 (Diaclone SAS, Besancon, France; lower
limit of detection (LLD) 4.94 ng/ml), soluble thrombomo-
dulin (sTM, Diaclone SAS, Besancon, France; LLD 0.31
ng/ml), soluble E-selectin (sE-selectin, sCD62E, Diaclone
SAS, Besancon, France; LLD < 0.5 ng/ml), vascular endo-
thelial (VE) cadherin (VE-cadherin, R&D Systems, Europe,
Ltd., Abingdon, UK; LLD 0.113 ng/ml), vascular endothe-
lial growth factor (VEGF, R&D Systems, Europe, Ltd.,
Abingdon, UK; LLD 9 pg/ml), histone-associated DNA
fragments (nucleosomes, Cell Death Detection ELISAPLUS,
Roche Diagnostics GmbH, Mannheim, Germany; LLD
relative percentage with a maximal standard included), fi-
brin monomer complex (Biocompare, LLD 1.56 μg/ml); fi-
brin degradation product (Cloud-Clone Corp., Houston,
USA; LLD 0.69 ng/ml), and D-dimer (Sekisui Diagnostics,
LLC, Stanford, CT, USA; LLD 2–4 ng/ml).
Statistical analysis
Summary statistics of continuous variables are presented
as median with interquartile range (IQR). Summary statis-
tics of frequency tables are presented as n (%). p values <
0.05 are considered significant.
The primary outcomes were analysed for efficacy in PP
analyses. The difference between treatment groups for
continuous data was evaluated with the analysis of vari-
ance (mixed model) and post hoc pairwise comparisons of
means. Furthermore, delta values (numerical change in
variables between time points) within and between groups
were compared by paired (Wilcoxon signed-rank test) and
non-paired (Mann-Whitney U test) non-parametric tests.
Biomarker measurements are presented as absolute
values in Figs. 2 and 3 and as relative changes in percent-
age from baseline in Additional file 4.
Secondary outcomes were analysed on an ITT basis.
The differences between treatment groups for categorical
data were evaluated with McNemar’s test (change over
time), frequency tables and chi-square statistics. The dif-
ference between treatment groups for continuous data
was evaluated using the analysis of variance (mixed
model) followed by post hoc pairwise comparisons of
means. If the assumption of normality was not fulfilled,
non-parametric test and Wilcoxon rank-sum test were
used. Statistical analysis was performed using SAS 9.1.3
SP4 (SAS Institute Inc., Cary, NC, US).
Results
During the study period, we screened 509 patients and
included 24. Most patients were excluded due to the ab-
sence of septic shock or completed/scheduled surgery
within ± 48 h. Of the included patients, two patients
were withdrawn prior to initiation of trial treatment, and
four patients were withdrawn prior to day 7 (Fig. 1).
These six patients were replaced in the trial. Reasons for
withdrawal were incorrect inclusion (1), emergency
surgery (1), transfer to another ICU (1), therapeutic
anticoagulation therapy (2) and treatment with inhaled
prostacyclin (1).
Table 1 shows baseline characteristics, use of organ
supportive therapy and outcomes of patients included in
the PP analyses. Only alkaline phosphatase was signifi-
cantly different between groups at baseline, and it is
worth noting that the disease severity was considerable
with SOFA scores of 8–10, SAPS II scores of 46–48 and
an observed 90-day mortality of 25–50%.
Primary outcomes
The PP primary analysis included data from the 18 pa-
tients (12 active and 6 placebo) who completed the full
7 days of the trial.
Berthelsen et al. Critical Care          (2019) 23:301 Page 4 of 10
Endothelial disruption biomarkers
At baseline, sVE-cadherin was significantly higher in the
placebo group (p = 0.047) (Fig. 2a). Apart from this,
there were no differences in the measured biomarkers
between groups at baseline or at any time point during
the 5-day follow-up (Fig. 2a–f). There were, however,
differences in the within-group changes over time: At 6
h, there was a significant increase in both sTM (p =
0.03) and nucleosomes (p = 0.02) (Fig. 2b, c) only in the
placebo group. Furthermore, in the placebo group, there
was a tendency towards increasing levels of nucleosomes
for up to 72 h (p = 0.06) (Fig. 2c).
At 48 h and throughout day 5, there was a significant de-
crease in sE-Selectin (p = 0.007) and sVEGFR1 (p = 0.005)
only in the active treatment group (Fig. 2d, e).
Platelet count
The platelet count did not differ significantly between
groups at any time point during the trial. Similarly to
the endothelial disruption biomarkers, there were differ-
ences in the within-group changes over time with a de-
cline from baseline to 48 h only in the placebo group
(p = 0.049) and an increase from baseline to day 7 only
in the active treatment group (p = 0.023) (Fig. 3a).
Fig. 1 Consort flow diagram. ICU intensive care unit, AMI acute myocardial infarction, A-line arterial line, PP per protocol, ITT intention to treat
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Fibrinolytic biomarkers
D-dimer and fibrinogen degradation products were simi-
lar in both groups (Fig. 3b, c). Levels of fibrin monomers
were higher in the active treatment group than in the
placebo group at baseline. Comparison of within-group
delta values showed a significant decline within the first
48 h (p = 0.048) and onwards only in the active treat-
ment group (time effect p = 0.04) (Fig. 3d).
Secondary outcomes
In the ITT secondary analyses, a total of 24 patients (15
active and 9 placebo) were included.
All secondary endpoints including safety measures of
bleeding, use of blood products in the ICU and mortality
were comparable between groups (Additional file 5).
Additionally, there was no difference in the occurrences
of serious adverse events (SAEs) between groups and
there were no suspected unexpected serious adverse re-
actions (SUSARs) in either group. Occurrences of SAEs
and reasons for withdrawal and exclusions are sum-
marised in Table 2.
Comparison of within-group changes over time re-
vealed a significant reduction in SOFA score at 48 h
(p = 0.024) and onwards in the active treatment group,
but not in the placebo group.
Discussion
Main findings
Dual therapy with iloprost and eptifibatide for 48 h in
patients with septic shock had no significant effect on
absolute values of biomarker levels compared to placebo
treatment.
Analysis of within-group changes over time revealed
biomarker changes indicative of reduced endothelial
Table 1 Baseline characteristics, use of organ support and
outcome of patients included in the per-protocol analyses
Variable Active
treatment
Placebo
treatment
Median (IQR) Median (IQR)
n 12 6
Age, years 61.5 (54.2–68.6) 71.3 (64.2–75)
Male gender, n (%) 8 (66.7%) 6 (100%)
BMI, kg/m2 24.5 (22.1–28.7) 27.8 (22.8–30.4)
Infectious focus
CNS, n (%) 0 (0%) 0 (0%)
Lungs, n (%) 10 (83.3%) 4 (66.7%)
Gastrointestinal, n (%) 0 (0%) 2 (33.3%)
Urogenital, n (%) 0 (0%) 0 (0%)
Skins and soft tissue, n (%) 2 (16.7%) 1 (16.7%)
Blood, n (%) 0 (0%) 1 (16.7%)
Unknown, n (%) 1 (8.3%) 0 (0%)
Identified pathogen
(microbiology), n (%)
9 (75%) 5 (83.3%)
Comorbidity
Chronic diagnosis, n (%) 9 (75%) 6 (100%)
Admitted from
Acute medical care unit, n (%) 6 (50%) 3 (50%)
Medical department, n (%) 3 (25%) 1 (16.7%)
Disease severity, physiology and biochemistry
SOFA (first) 9.0 (7.8–12.0) 9.5 (7.3–13.3)
SAPS II 46 (42–57) 48 (39–55)
Systolic blood pressure, mmHg 113 (100–120) 123 (104–145)
Lactate, mmol/l 1.4 (1.3–3.1) 3.5 (1.9–3.9)
pH 7.35 (7.3–7.41) 7.41 (7.39–7.41)
Haemoglobin, mmol/l 6.9 (6.4–7.7) 6.5 (5.8–7)
White blood cell count, × 109/l 15 (9.8–19.1) 17.2 (8.8–23.1)
Platelet count, ×109/l 188 (130–255) 212 (149–295)
INR 1.2 (1.1–1.2) 1.3 (1.1–2)
Antithrombin 0.64 (0.52–0.76) 0.58 (0.37–0.82)
D-dimer 4.6 (2.4–19.9) 14.4 (3.4–15.3)
Creatinine, μmol/l 97 (67–242) 126 (114–189)
Blood urea nitrogen (BUN), mmol/l 7.9 (5.3–13.2) 13.5 (8.6–17.9)
ALAT, U/l 35 (26–62) 35 (23–169)
Bilirubin, μmol/l 11 (5–24) 16 (8–29)
Basic phosphatase, U/l 64 (57–84) 149 (76–242)
C-reactive protein, mg/l 172 (129–244) 138 (89–169)
Therapy and outcome
Ventilator days, n (%) 5 (3–6) 6 (4–6)
Ventilator-free days, n (%) 25 (24–27) 24 (6–24)
RRT days, n (%) 0 (0–0) 0 (0–0)
RRT-free days, n (%) 30 (29–30) 30 (8–30)
Table 1 Baseline characteristics, use of organ support and
outcome of patients included in the per-protocol analyses
(Continued)
Variable Active
treatment
Placebo
treatment
Median (IQR) Median (IQR)
Vasopressor days, n (%) 5 (5–5) 5 (4–5)
Vasopressor-free days, n (%) 25 (24–25) 25 (6–25)
Discharged to admitting dept., n (%) 9 (75%) 3 (50%)
Discharged to other hosp., n (%) 1 (8.3%) 1 (16.7%)
Discharged to other ICU, n (%) 1 (8.3%) 1 (16.7%)
Active stop therapy, n (%) 2 (16.7%) 1 (16.7%)
7-day mortality, n (%) 0 (0%) 1 (16.7%)
30-day mortality, n (%) 1 (8.3%) 2 (33.3%)
90-day mortality, n (%) 3 (25%) 3 (50%)
IQR interquartile range, BMI body mass index, CNS central nervous system,
SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology
Score II, INR international normalised ratio, ALAT alanine aminotransferase, RRT
renal replacement therapy, ICU intensive care unit, NS non-significant
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injury, reduced fibrinolysis and reduced platelet con-
sumption in the active treatment group. This was ac-
companied by an overall decline in SOFA score from 48
h and onwards that was not observed in the placebo-
treated patients. Additionally, the trial treatment was not
associated with increased bleeding or the use of blood
products as compared to placebo.
Endothelial injury
Taken together, the observed changes in sTM, nucleo-
somes, sE-selectin, VEGF and sVEGFR1 could reflect
reduced levels of endothelial activation, disruption and
cell damage.
Prostacyclin doses, corresponding to the low dose
chosen for this trial (1.0 ng/kg/min), have previously
been demonstrated not to increase bleeding risk or
haematoma size in patients with traumatic brain injury
[17] and to reduce the need for blood transfusion in pa-
tients undergoing Whipple surgery due to pancreatic
cancer [25]. Our results are in alignment with these
former trials which also demonstrated beneficial effects
of iloprost on vascular integrity in critically ill patients
reflected by similar changes in sE-selectin, sTM and nu-
cleosomes [17, 25, 26].
Endothelial protection could be ascribed to the cyto-
protective effects of prostacyclin, which in its endogen-
ous form induces a reduction in inflammation and
stabilisation of lysosomal and cell membranes [27]. The
dose of 1.0 ng/kg/min is approximately five- to tenfold
higher than the normal endogenous production of pros-
tacyclin from the healthy endothelium [28], and we ex-
pected this to restore vascular integrity in septic patients
with endothelial injury and dysfunction.
Fig. 2 a–g Comparison of time-dependent changes in absolute biomarker values. Data shown as median (IQR). *Within-group change from
baseline, p < 0.05; #within-group change from non-baseline, p < 0.05. sVEGFRI soluble vascular endothelial growth factor receptor 1
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Fig. 3 a–d Comparison of time-dependent changes in platelet count, D-dimer, Fibrin monomers and SOFA score. Data shown as median (IQR).
*Within-group change from baseline, p < 0.05; #within-group change from non-baseline, p < 0.05. SOFA Sequential Organ Failure Assessment
Table 2 SAE/withdrawal/exclusion
ITT/PP Allocation
[duration]
SAE/withdrawal/exclusion Outcome
ITT Placebo [0 h] Recovery with extubation before trial drug administration (incl. criteria not met).
Excluded
Death on day 13 (resp. failure)
ITT Placebo [14 h] Thrombosis in the arterial cannula (difficult insertion in Aa. radialis, instead US-guided
insertion in a. brachialis). SAE/withdrawal
LMWH treatment (10.000 IE)
with good effect. Survivor
ITT Placebo [14 h] Indication for Flolan inhalation (severe respiratory failure). SAE/withdrawal Death on day 2
(respiratory failure)
PP Placebo [completed] Iatrogenic pneumothorax and intraabdominal bleeding after liver abscess drainage, 28 h
after ceasing trial drug. SAE
Death on day 2 (pneumonia)
ITT Active [0 h] Indication for acute abdominal surgery before trial drug administration. Excluded Survivor
ITT Active [21 h] Indication for therapeutic LMWH (suspicion of type II MI). Cardiac enzymes elevated before
inclusion, but increasing. SAE/withdrawal
Death on day 10
(cardiac failure)
ITT Active [28 h] Transferred to other ICU due to overcrowding. Withdrawal Survivor
PP Active [complete] Severe septic shock (Capnocytophagus carnimorsus) with bradycardia treated with 1 mg
adrenalin IV and 2min CPR. Circulatory stabilised after 2 min. Transferred to tertiary ICU
day 4. Necrotomy of the face and leg day 27. Finger amputation (1., 2., 4., 5. finger on
the left hand) day 35. Femur amputation day 50. SAE
Survivor
ITT intention to treat, PP per protocol, SAE serious adverse event, US ultrasound, LMWH low molecular weight heparin, MI myocardial infarction, ICU intensive care
unit, IV intravenous, CPR cardiopulmonary resuscitation
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The clinical impact of within-group changes in these
biomarkers remains to be seen, but observational data
have linked increased levels of sTM to reduced survival
in patients with septic shock [29].
Platelet protection and thrombotic activity
The increasing platelet count in the active treatment
group could indicate protective effect against platelet
consumption. In a previous study by Link et al., it was
demonstrated that administration of a platelet GPIIb/IIIa
receptor inhibitor in combination with unfractionated
heparin for 96 h was tolerated in patients with cardio-
genic shock and need for dialysis. Importantly, in this
study, treatment with the GPIIb/IIIa receptor inhibitor
was not associated with increased bleeding but was ra-
ther associated with a significantly lower number of
platelet transfusions and a higher, maintained platelet
count, as compared to controls anticoagulated with hep-
arin alone [30]. This finding of preserved platelet count
is in accordance with the finding in our study.
In addition to preserved platelet counts, the inhibition
of platelet-monocyte aggregation might have an anti-in-
flammatory effect, and thus serve to protect the endo-
thelium and microvasculature [31]. A reduced
thrombotic activity was reflected in declining levels of fi-
brin monomers in the active treatment group.
Safety
The individual doses of iloprost and eptifibatide selected
for this trial are lower than the recommended doses for
their respective approved indications. The dosages
chosen for the current trial are in alignment with doses
that have been reported to result in the desired effect for
each agent without causing significant adverse side ef-
fects [17, 25, 30].
The safety of the co-administration of eptifibatide and
iloprost in a dose comparable to the dose applied in the
present study (eptifibatide 0.5 μg/kg/min + iloprost 1.0
ng/kg/min infused for 24 h) is supported by a completed
phase I/II trial in patients undergoing primary PCI due
to ST-elevated myocardial infarct [26]. This trial found
no bleeding-related adverse events, and no treatment-re-
lated adverse events occurred.
Limitations
Our main inclusion criterion was septic shock defined as
the use of norepinephrine in patients with sepsis. This
ensured that the screening and inclusion process was ra-
ther pragmatic and easy to perform, but we might have
limited the potential effect of our intervention, since it is
not given that all patients with septic shock have equal
degrees of endothelial dysfunction and/or consumption
coagulopathy. If we had used one or more specific
markers in our screening, we might have been able to
show higher efficacy of our trial treatment.
The CO-ILEPSS pilot trial is exploratory and hypothesis
generating. Our small sample size and the single-centre
design limit both external validity and the ability to draw
any definitive conclusions from our results. The lack of a
power calculation might have limited our ability to detect
a difference in our primary outcome. Furthermore, our
primary outcome is a composite of three categories of bio-
markers with a total of 11 sub-components, which poses a
problem of multiplicity.
Conclusion
The results of the CO-ILEPSS trial suggest that dual ther-
apy with iloprost and eptifibatide for 48 h in patients with
septic shock is safe and may even be beneficial. Biomarker
measurements indicated reduced endothelial activation,
disruption and cell damage, accompanied by less severe
thrombocytopenia. Interestingly, the dual treatment re-
sulted in significant reductions in SOFA score after 48 h
compared to placebo treatment. Future adequately pow-
ered trials are warranted to reveal if this treatment may
lead to improved patient-centred outcomes.
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